MX2022011333A - Compuestos moduladores de gpr52. - Google Patents
Compuestos moduladores de gpr52.Info
- Publication number
- MX2022011333A MX2022011333A MX2022011333A MX2022011333A MX2022011333A MX 2022011333 A MX2022011333 A MX 2022011333A MX 2022011333 A MX2022011333 A MX 2022011333A MX 2022011333 A MX2022011333 A MX 2022011333A MX 2022011333 A MX2022011333 A MX 2022011333A
- Authority
- MX
- Mexico
- Prior art keywords
- gpr52
- modulator compounds
- formula
- receptors
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Abstract
Las divulgaciones contenidas en el presente documento se refieren a novedosos compuestos de la fórmula (1): (ver Fórmula) (1) y a las sales de los mismos, en donde X, Y, R1, R2, R3 y R4 se definen en el presente documento, y a su uso en el tratamiento, la prevención, la mejora, el control o la reducción del riesgo de los trastornos asociados con los receptores GPR52.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2003668.7A GB202003668D0 (en) | 2020-03-13 | 2020-03-13 | GPR52 Modulator compounds |
| PCT/GB2021/050638 WO2021181122A1 (en) | 2020-03-13 | 2021-03-15 | Gpr52 modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011333A true MX2022011333A (es) | 2022-12-08 |
Family
ID=70453676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011333A MX2022011333A (es) | 2020-03-13 | 2021-03-15 | Compuestos moduladores de gpr52. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240254101A1 (es) |
| EP (1) | EP4117784B1 (es) |
| JP (1) | JP7492597B2 (es) |
| KR (1) | KR20220152296A (es) |
| CN (1) | CN115515681B (es) |
| AU (1) | AU2021235257A1 (es) |
| BR (1) | BR112022018287A2 (es) |
| CA (1) | CA3175429A1 (es) |
| DK (1) | DK4117784T3 (es) |
| ES (1) | ES2992600T3 (es) |
| FI (1) | FI4117784T3 (es) |
| GB (1) | GB202003668D0 (es) |
| HR (1) | HRP20241375T1 (es) |
| HU (1) | HUE068758T2 (es) |
| IL (1) | IL296413B1 (es) |
| LT (1) | LT4117784T (es) |
| MX (1) | MX2022011333A (es) |
| PL (1) | PL4117784T3 (es) |
| PT (1) | PT4117784T (es) |
| RS (1) | RS66063B1 (es) |
| SI (1) | SI4117784T1 (es) |
| SM (1) | SMT202400402T1 (es) |
| WO (1) | WO2021181122A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| WO2022232017A1 (en) * | 2021-04-26 | 2022-11-03 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| AR130864A1 (es) * | 2022-10-26 | 2025-01-29 | Neurocrine Biosciences Inc | Compuestos y composiciones como moduladores de gpr52 |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| WO2025252061A1 (zh) * | 2024-06-04 | 2025-12-11 | 海思科医药集团股份有限公司 | 一种gpr52激动剂及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005037797A1 (en) * | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| EP2518054A1 (en) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Amide compound |
| WO2011093352A1 (ja) | 2010-01-27 | 2011-08-04 | 武田薬品工業株式会社 | チアゾール誘導体 |
| ES2784316T3 (es) * | 2015-04-29 | 2020-09-24 | Arena Pharm Inc | 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo |
| US10633350B2 (en) | 2017-09-13 | 2020-04-28 | Novartis Ag | Diphenyl derivatives and uses thereof |
-
2020
- 2020-03-13 GB GBGB2003668.7A patent/GB202003668D0/en not_active Ceased
-
2021
- 2021-03-15 SI SI202130212T patent/SI4117784T1/sl unknown
- 2021-03-15 CA CA3175429A patent/CA3175429A1/en active Pending
- 2021-03-15 PT PT217131036T patent/PT4117784T/pt unknown
- 2021-03-15 KR KR1020227035100A patent/KR20220152296A/ko active Pending
- 2021-03-15 US US17/909,792 patent/US20240254101A1/en active Pending
- 2021-03-15 LT LTEPPCT/GB2021/050638T patent/LT4117784T/lt unknown
- 2021-03-15 PL PL21713103.6T patent/PL4117784T3/pl unknown
- 2021-03-15 BR BR112022018287A patent/BR112022018287A2/pt unknown
- 2021-03-15 RS RS20241089A patent/RS66063B1/sr unknown
- 2021-03-15 SM SM20240402T patent/SMT202400402T1/it unknown
- 2021-03-15 IL IL296413A patent/IL296413B1/en unknown
- 2021-03-15 ES ES21713103T patent/ES2992600T3/es active Active
- 2021-03-15 FI FIEP21713103.6T patent/FI4117784T3/fi active
- 2021-03-15 HR HRP20241375TT patent/HRP20241375T1/hr unknown
- 2021-03-15 DK DK21713103.6T patent/DK4117784T3/da active
- 2021-03-15 MX MX2022011333A patent/MX2022011333A/es unknown
- 2021-03-15 EP EP21713103.6A patent/EP4117784B1/en active Active
- 2021-03-15 CN CN202180033813.9A patent/CN115515681B/zh active Active
- 2021-03-15 AU AU2021235257A patent/AU2021235257A1/en active Pending
- 2021-03-15 WO PCT/GB2021/050638 patent/WO2021181122A1/en not_active Ceased
- 2021-03-15 HU HUE21713103A patent/HUE068758T2/hu unknown
- 2021-03-15 JP JP2022555137A patent/JP7492597B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT4117784T (pt) | 2024-10-07 |
| PL4117784T3 (pl) | 2025-01-13 |
| LT4117784T (lt) | 2024-10-25 |
| KR20220152296A (ko) | 2022-11-15 |
| DK4117784T3 (da) | 2024-10-14 |
| HUE068758T2 (hu) | 2025-01-28 |
| HRP20241375T1 (hr) | 2024-12-20 |
| CN115515681A (zh) | 2022-12-23 |
| CN115515681B (zh) | 2024-09-03 |
| CA3175429A1 (en) | 2021-09-16 |
| GB202003668D0 (en) | 2020-04-29 |
| WO2021181122A1 (en) | 2021-09-16 |
| US20240254101A1 (en) | 2024-08-01 |
| JP2023519666A (ja) | 2023-05-12 |
| EP4117784A1 (en) | 2023-01-18 |
| JP7492597B2 (ja) | 2024-05-29 |
| EP4117784B1 (en) | 2024-08-28 |
| IL296413B1 (en) | 2025-11-01 |
| IL296413A (en) | 2022-11-01 |
| ES2992600T3 (en) | 2024-12-16 |
| BR112022018287A2 (pt) | 2022-11-22 |
| RS66063B1 (sr) | 2024-11-29 |
| AU2021235257A1 (en) | 2022-10-06 |
| FI4117784T3 (fi) | 2024-10-10 |
| SI4117784T1 (sl) | 2025-03-31 |
| SMT202400402T1 (it) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011333A (es) | Compuestos moduladores de gpr52. | |
| MX2022005111A (es) | Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52). | |
| MX2020000261A (es) | Nuevos compuestos. | |
| MX2022010040A (es) | Compuestos moduladores de gcn2. | |
| CL2023003041A1 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica | |
| ECSP21033236A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| AR122973A1 (es) | Compuestos de piperidina sustituida y su uso | |
| CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
| MX2021013854A (es) | Compuestos para tratar enfermedad de huntington. | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| AR064420A1 (es) | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
| MX9204703A (es) | Acidos n-acil-n-heterociclilalquilamino, proceso para su obtencion y composicion farmaceutica que los contiene. | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| CL2024000742A1 (es) | Compuestos moduladores de gpr52 | |
| CL2020003248A1 (es) | Derivados de tetrahidrotienopiridina n-sustituidos y sus usos | |
| MX390507B (es) | Compuestos de amida y su uso. | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. |